Bimatoprost/timolol
Combination of | |
---|---|
Bimatoprost | Prostaglandin analogue |
Timolol | Beta blocker |
Clinical data | |
Trade names | Ganfort |
AHFS/Drugs.com | UK Drug Information |
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Bimatoprost/timolol, sold under the brand name Ganfort, is a
It was approved for medical use in the European Union in May 2006.[3]
Medical uses
Bimatoprost/timolol is used for the treatment of open angle glaucoma or ocular hypertension in people for whom single-component eye drops such as prostaglandin analogs or beta blockers are insufficient.[4]
Contraindications
Because of the timolol component, which is a beta blocker, the drops are contraindicated in people with lung problems such as
Adverse effects
The most common side effect is
Hyperpigmentation is an adverse effect of bimatoprost,[5] while the others are fairly common for eye drops in general.
Interactions
No formal interaction studies have been done with bimatoprost/timolol eye drops. As timolol (in tablet form) can be used to lower blood pressure and heart rhythm, it might add to the effect of other
Pharmacology
Bimatoprost is a
References
- ^ a b c "Ganfort 0.3 mg/ml + 5 mg/ml eye drops, solution - Summary of Product Characteristics (SmPC)". (emc). 20 February 2020. Retrieved 1 March 2020.
- ^ "Ganfort 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container - Summary of Product Characteristics (SmPC)". (emc). 25 February 2020.
- ^ a b c d "Ganfort EPAR". European Medicines Agency (EMA). 26 February 2020. Retrieved 1 March 2020.
- ^ a b c d e "Ganfort: EPAR – Product information" (PDF). European Medicines Agency. 26 February 2020.
- ^ "Bimatoprost solution/drops". DailyMed. 18 September 2019.
Further reading
- Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL (2012). "Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis". PLOS ONE. 7 (9): e45079. PMID 23028770.
- Fang Y, Ling Z, Sun X (2015). "Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol". Drug Design, Development and Therapy. 9: 2617–25. PMID 25999695.
- Guven Yilmaz S, Degirmenci C, Karakoyun YE, Yusifov E, Ates H (August 2018). "The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP". International Ophthalmology. 38 (4): 1425–1431. S2CID 4019275.
- Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, Floriani I (May 2013). "Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis". Journal of Ocular Pharmacology and Therapeutics. 29 (4): 382–9. PMID 23231442.
- Xing Y, Zhu L, Zhang K, Huang S (2020). "The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis". PLOS ONE. 15 (2): e0229682. PMID 32106236.
External links
- "Bimatoprost". Drug Information Portal. U.S. National Library of Medicine.
- "Timolol Ophthalmic". Drug Information Portal. U.S. National Library of Medicine.